CD86 and neoplasm: These findings collectively underscore that tumor-directed, sequenced immunoradiotherapy not only enhances the migratory potential of CD86/CD40/MHCII/CD11c+ dendritic cells to the SLN but, more importantly, supports a model in which these cells undergo functional reprogramming.